Alluvi, known as BI 4744, represents a promising breakthrough in weight management care. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates compelling effectiveness in clinical https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/